---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-012106"
form_type: "8-K"
ticker: "LMAT"
cik: "0001158895"
company_name: "LEMAITRE VASCULAR INC"
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T02:43:02.680438+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LeMaitre Q1 sales up 22% organic to $47.1M; EPS flat at $0.27; issues guidance

## Summary
- Sales $47.1M, +19% (+22% organic); net income $6.0M flat; diluted EPS $0.27 (-1%).
- Valvulotomes (+29%), carotid patches (+17%), bovine grafts (+22%), allografts (+42%), carotid shunts (+18%) led record Q1 sales.
- Q2 2023 guidance: sales $47.1M–$49.5M; EPS $0.30–$0.35. Full year: sales $187.1M–$193.1M; EPS $1.14–$1.27.
- Quarterly dividend $0.14/share, payable June 1, 2023 to holders of record May 17, 2023.
- Agreed to distribute Aziyo porcine cardiac patches in US for three years (option to acquire); Aziyo's 2022 US patch sales $6.8M.

## SEC filing metadata
- accession: 0001437749-23-012106
- form_type: 8-K
- ticker: LMAT
- cik: 0001158895
- company_name: LEMAITRE VASCULAR INC
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158895/000143774923012106/0001437749-23-012106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158895/000143774923012106/lmat20230502_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-012106
- JSON: https://secwatch.observer/filing/0001437749-23-012106.json
- Plain text: https://secwatch.observer/filing/0001437749-23-012106.txt

## Key facts
- Earnings Releases
  LEMAITRE VASCULAR INC updated its the quarter ended March 31, 2023 guidance (initiated).
  - Period: the quarter ended March 31, 2023
  - Guidance: initiated
  - Result: preliminary results
  source text: On May 2, 2023, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1158895/000143774923012106/0001437749-23-012106-index.htm
- Earnings Releases
  LEMAITRE VASCULAR INC reported Q1 2023 results: revenue $47.1mm, net income $6.0mm, EPS $0.27. Guidance initiated.
  - Period: Q1 2023
  - Revenue: $47.1mm
  - Net income: $6.0mm
  - EPS: $0.27
  - Guidance: initiated
  - Result: reported results
  source text: devices, implants and services, today reported Q1 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q1 2023 Financial Results ● Sales $47.1mm, +19% (+22% organic) vs. Q1 2022 ● Op. income $7.9mm, -1% ● Op. margin 17% ● Net income $6.0mm, flat ● Earnings per diluted share $0.27, -1%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1158895/000143774923012106/0001437749-23-012106-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.